User Stats

Total reviews: 2
Level: Guru
Member Since: 19/05/2022

Profile Information

First name Rakhan
Last name Aimbetov
I have professional experience in:

Biotech, Therapeutics, Regulatory

Help us confirm that you're an expert

– I work in the cell/molecular biology field.
– I studied the mTOR pathway in graduate school; as a postdoc, I worked on the association of uncanonical histone variants with transcriptional regulators in the breast cancer context; as a second postdoc, I studied the role of DJ-1/PARK7 enzyme in early-onset Parkinson’s disease.
– As a visiting fellow at Nazarbayev University, I investigate the effect of glycation of ribosomes–i.e. post-translational non-enzymatic modifications of ribosomal proteins and rRNAs by glycolysis-derived metabolite methylglyoxal–on protein biosynthesis fidelity.
– I’m an active contributor to decentralized science/Web3 organizations – VitaDAO, LabDAO, MedDAO, etc.
– I’m an analyst for Longaevus Technologies, a longevity biotechnology company.
– In 2023, I founded a project to engineer enzymes that would degrade advanced glycation end products in the extracellular matrix.

LinkedIn

http://www.linkedin.com/in/raimbetov

How did you hear about us?

Through a colleague who provides expertise to the network.

Base
Name

Rakhan Aimbetov

I have professional experience in:

Biotech, Therapeutics, Regulatory

Help us confirm that you're an expert

– I work in the cell/molecular biology field.
– I studied the mTOR pathway in graduate school; as a postdoc, I worked on the association of uncanonical histone variants with transcriptional regulators in the breast cancer context; as a second postdoc, I studied the role of DJ-1/PARK7 enzyme in early-onset Parkinson’s disease.
– As a visiting fellow at Nazarbayev University, I investigate the effect of glycation of ribosomes–i.e. post-translational non-enzymatic modifications of ribosomal proteins and rRNAs by glycolysis-derived metabolite methylglyoxal–on protein biosynthesis fidelity.
– I’m an active contributor to decentralized science/Web3 organizations – VitaDAO, LabDAO, MedDAO, etc.
– I’m an analyst for Longaevus Technologies, a longevity biotechnology company.
– In 2023, I founded a project to engineer enzymes that would degrade advanced glycation end products in the extracellular matrix.

LinkedIn

http://www.linkedin.com/in/raimbetov

How did you hear about us?

Through a colleague who provides expertise to the network.